Michael Gibson

Michael Gibson, MD, PhD
October 30, 2024

Michael Gibson votes with FDA panel to limit immunotherapy indication 

The panel determined that allowing the wider indication would put patients at risk for adverse reactions from the two immunotherapies but without the added benefit in survival. 

By Tom Wilemon
x-ray of stomach
October 12, 2023

Symposium for patients, caregivers and family members offers important information on stomach cancer, Nov. 4

A Vanderbilt symposium on Nov. 4 offers detailed information for patients, caregivers and family members about stomach cancer.

By Tom Wilemon
April 27, 2023

Trial combines novel therapies for head and neck cancer

Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.

By Tom Wilemon
Twenty-four hours after the administration of the study drug, catheters are inserted into the tumor and lasers emitting a wavelength of light that activates the dye molecule on the ASP-1929 are illuminated.
October 14, 2021

Photoimmunotherapy offered in clinical trial for recurrent head and neck cancer

Vanderbilt-Ingram Cancer Center is recruiting patients for a clinical trial using photoimmunotherapy for recurrent head and neck cancer.

By Tom Wilemon